clopidogrel / Generic mfg. - LARVOL DELTA

Biphasic dysglycemia induced by pentamidine and detected by intermittently scanned continuous glucose monitoring: a case report of a possible drug-drug interaction with clopidogrel and literature review. (PubMed, J Pharm Health Care Sci) - No abstract available

Journal • Diabetes • Hypoglycemia

Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of CG-0255 and its active metabolite in human plasma and its application to Phase I studies. (PubMed, J Pharm Biomed Anal) - "CG-0255, a thiol prodrug of clopidogrel's active metabolite H4 (CG-0236), is a novel thienopyridine P2Y12 receptor antagonist under initial clinical development for the treatment of acute coronary syndromes...The validated assay was successfully applied to two phase I clinical studies conducted at our center, characterizing the pharmacokinetics of CG-0255 following single-dose intravenous and multiple-dose oral administration. This UHPLC-MS/MS method provides a reliable platform for the quantitative evaluation of CG-0255 and its active metabolite in human plasma, and is well suited to support further global clinical development."

Journal • P1 data • Acute Coronary Syndrome • Cardiovascular

Antiplatelet and Anticoagulation Impact on Patients with Lower Extremity Arteriovenous Dialysis Access. (PubMed, Ann Vasc Surg) - "This analysis suggests SAPT is protective for lower extremity AVG with clopidogrel alone showing statistically significant protection. This suggests that clopidogrel as SAPT is a viable option for prolonging AVG patency if prescribed at discharge. Further study on antiplatelet usage following lower extremity dialysis access creation is warranted."

Journal

Effects of Alteplase, Aspirin, and Clopidogrel on Inflammatory Factors and Neurological Function in Patients with Stroke. (PubMed, Int J Neurosci) - "At the 90-day follow-up, the triple-agent group demonstrated significantly better upper and lower limb function and higher Barthel scores compared with the dual-agent group (P < 0.001). Triple-agent therapy, with alteplase, aspirin, and clopidogrel, may reduce neurological impairment, improve cognitive outcomes, and enhance early functional recovery in patients with stroke, although at the expense of higher medical costs."

Journal • Cardiovascular

A randomized controlled trial on the efficacy and safety of enhanced external counterpulsation in combination with mechanical thrombectomy for treating acute large vessel occlusive ischemic stroke (ChiCTR) - P=N/A | N=90 | Recruiting | Sponsor: The Second People's Hospital of Hefei; The Second People's Hospital of Hefei

New trial • Cardiovascular • Ischemic stroke

Intravenous thrombolysis and antiplatelet therapy of acute minor stroke: a systematic review and pairwise and bayesian network meta-analysis of randomized controlled trials (ISC 2026) - "Subgroup analyses ranked the effects of different antiplatelet regimens (e.g., dual antiplatelet therapy [DAPT], aspirin monotherapy) and thrombolytic agents (e.g., alteplase, tenecteplase) on 90-day functional outcomes, symptomatic intracranial hemorrhage (sICH), and all-cause mortality. Pairwise meta-analysis revealed no significant difference between the IVT and SMT groups in achieving excellent functional outcomes at 90 days (modified Rankin Scale [mRS] 0–1: odds ratio [OR] 0.85, 95% confidence interval [CI] 0.72–1.00) or good functional outcomes (mRS 0–2: OR 0.81, 95% CI 0.65–1.01), whereas IVT was associated with a markedly increased risk of sICH (OR 5.17, 95% CI 1.97–13.55). In patients with mild ischemic stroke within 12 hours of onset, SMT is noninferior to IVT and significantly reduces the risk of sICH. Among SMT regimens, dual antiplatelet therapy (DAPT) based on aspirin and clopidogrel may represent the optimal treatment option that balances both efficacy..."

Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: an updated meta-analysis of 162,829 patients. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • Monotherapy • Retrospective data • Review • Cardiovascular

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: University of Florida | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease • Myocardial Infarction

TAVR-ELECTRO: Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement (clinicaltrials.gov) - P=N/A | N=1000 | Active, not recruiting | Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital

New trial • Cardiovascular

CLOPI-SNAP: Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - P2 | N=230 | Not yet recruiting | Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

New P2 trial

Knowledge domain and evolutionary trends of P2Y receptors in cardiovascular diseases: a bibliometric and altmetric analysis. (PubMed, Front Pharmacol) - "The research focus has shifted from the antithrombotic mechanisms of early P2Y12 inhibitors like clopidogrel toward immune inflammation, myocardial regeneration, and precision medicine...While P2Y12 antagonists remain clinically dominant, emerging frontiers focus on "de-escalation" strategies, immune-inflammation, and myocardial regeneration. Future progress relies on systematic evaluation of subtype selectivity and novel delivery systems, positioning P2Y receptor modulation as a promising avenue for precision cardiovascular medicine."

Journal • Review • Cardiovascular • Inflammation

Primary antiphospholipid syndrome complicated by recurrent acute ST-elevation myocardial infarction: a case report. (PubMed, Front Cardiovasc Med) - "A personalized treatment regimen combining clopidogrel, low-molecular-weight heparin, methylprednisolone, hydroxychloroquine, and rituximab was administered, which resulted in a favorable long-term prognosis. This case underscores the importance of a multidisciplinary approach and individualized treatment strategies based on coronary functional assessment for managing patients with PAPS and AMI."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Myocardial Infarction • Thrombocytopenia

Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y12 Inhibitor Therapy. (PubMed, JACC Adv) - "Higher SDI was associated with an increased risk of MAE with clopidogrel and bleeding with alternative therapy following PCI. Whether addressing socioeconomic disparities improves P2Y12 inhibitor-related outcomes remains to be determined."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis

Rebound Phenomenon of Platelet Reactivity After Cessation of Long-Term Clopidogrel Therapy. (PubMed, JACC Asia) - No abstract available

Journal

Post-Thrombolysis Antiplatelet Strategies and Functional Recovery in Mild Ischemic Stroke with Disabling Symptoms: A Retrospective Cohort Study. (PubMed, Neurol India) - "Tirofiban bridging followed by dual antiplatelet therapy may enhance early neurological recovery and long-term functional outcomes without increasing bleeding risk in MIS patients with disabling symptoms or END."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Guideline-based diagnostics and treatment of peripheral arterial occlusive disease : Updates in the current guidelines, implications of the German hospital reform and practice-relevant knowledge for all surgeons (PubMed, Chirurgie (Heidelb)) - "Treatment management emphasizes strict secondary prevention (low-density lipoprotein, LDL < 3,1 mmol/l, smoking cessation), supervised exercise training and optimized antithrombotic therapy (clopidogrel is preferred; dual pathway inhibition for high-risk patients or after revascularization). Revascularization can be performed endovascularly or surgically and increasingly in specialized centers. The German Hospital Reform supports the centralization of complex procedures and the expansion of outpatient care, thereby underscoring the pivotal role of nonvascular surgical departments in early detection and coordinated referral."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Peripheral Arterial Disease • Tobacco Cessation

From pelvis to heart: A rare case of infective endocarditis following ASD device closure due to tubo-ovarian abscess. (PubMed, J Cardiol Cases) - "Despite an uneventful early post-procedure course, her worsening uterine bleeding led to clopidogrel discontinuation...It emphasizes the importance of considering distant infection sources, such as tubo-ovarian abscesses, in patients presenting with post-procedural complications. Furthermore, it underscores the necessity of multidisciplinary collaboration, and prolonged antibiotic therapy and surgical intervention for successful patient outcomes."

Journal • Anesthesia • Cardiovascular • Endometriosis • Gynecology • Infectious Disease • Solid Tumor • Uterine Leiomyoma • Women's Health

In patients with CAD, clopidogrel vs. aspirin monotherapy reduces MACCE without increasing major bleeding. (PubMed, Ann Intern Med) - "GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text]."

Journal • Monotherapy • Cardiovascular

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST-Elevation Myocardial Infarction: A Case Report. (PubMed, Clin Case Rep) - "She was treated with oral aspirin, clopidogrel, atorvastatin, intravenous enoxaparin, tenecteplase (30 mg), and subcutaneous enoxaparin. In conclusion, tenecteplase can result in concurrent CNS hemorrhages even in the absence of vascular anomalies or coagulation defects. Clinicians should remain vigilant for both cranial and spinal hemorrhagic complications even with fibrin-specific agents like tenecteplase."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction • Pain

In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 y. (PubMed, Ann Intern Med) - "GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text]."

Adverse events • Journal • Cardiovascular

Decreased Silent Brain Ischemic Lesions Following Aneurysm Flow Diversion with Intraoperative Eptifibatide: A Retrospective Study and a Meta-Analysis (ISC 2026) - "Higher (> mean) fluoroscopy time (OR 15.42, 95% CI 2.64–90.00, p = 0.002), higher (> mean) fluoroscopy dose (OR 6.88, 95% CI 1.35–34.97, p = 0.020), and ASA/Plavix DAPT regimen (OR 9.33, 95% CI 1.05–82.78, p = 0.045) were significantly associated with DWI lesion occurrence. The overall pooled incidence of DWI lesions was 56% (95% CI: 32%–77%). The rate of DWI lesions in our cohort was significantly lower than in the pooled cohort (OR = 0.11, 95% CI = [0.043–0.24], p < 0.001) and seven of the eight individual cohorts (all p≤0.002).ConclusionsIntraoperative eptifibatide may decrease the incidence of DWI lesions during flow diversion procedures without increasing the risk for hemorrhagic complications."

Retrospective data • Cardiovascular • Hematological Disorders • Vascular Neurology

Clinical management and outcomes for 51 Pugs reportedly diagnosed with protein-losing enteropathy using VetCompass primary care veterinary data. (PubMed, J Small Anim Pract) - "Studies that account for severity of disease are needed to determine if Pugs with protein-losing enteropathy managed completely in primary care have similar outcomes versus referral. Prednisolone and clopidogrel may increase short-term survival; however, prospective studies are needed to confirm this."

Journal

A study on the safety and efficacy of tirofiban in elderly patients with acute cerebral infarction (ChiCTR) - P4 | N=360 | Recruiting | Sponsor: Hengzhou People’s Hospital; Hengzhou People’s Hospital

New P4 trial • Cardiovascular • CNS Disorders • Ischemic stroke

Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study. (PubMed, Lancet) - "The ONCO-ACS score provides a validated practical tool for predicting mortality, bleeding, and ischaemic risk in patients with cancer and acute coronary syndrome. Combined assessment of competing outcome risks could facilitate balancing treatment benefits and harms."

Journal • Acute Coronary Syndrome • Cardiovascular • Ischemic stroke • Myocardial Infarction • Oncology

Comparative Study of Treatment Strategies for Migraine in Patients with Patent Foramen Ovale (PFO): A Multicenter Randomized Controlled Trial of Transcatheter Closure versus Medical Therapy (ChiCTR) - P=N/A | N=150 | Recruiting | Sponsor: The Seventh Affiliated Hospital Sun Yat-sen University; The?Seventh?Affiliated?Hospital?Sun?Yat-sen?University

New trial • CNS Disorders • Migraine • Pain